Health Condition 1: I10- Essential (primary) hypertension
Conditions
Interventions
Intervention1: Single Pill Combination of Amlodipine and Perindopril: 1. Amlodipine 5mg and Perindopril 4 mg once daily.
2. Amlodipine 10mg and Perindopril 8 mg once daily [If target control of blood
Sponsors
Imperial College of London
Shri Dharmasthala Manjunatheshwara University
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with Sitting clinic values of Systolic blood pressure between 140 mmHg and 160 mmHg on one antihypertensive agent OR 2. Patient with Sitting clinic values of Systolic Blood Pressure between 150 mmHg and 180 mmHg on no antihypertensive treatment
Exclusion criteria
Exclusion criteria: 1. Congestive heart failure (clinically defined). 2. Patients with a history of intolerance to any of the study medications for example angioedema or dry cough with ACE-inhibitors. 3. Serum creatinine levels greater than 132.6 µmol/l (1.5mg/dl) 4. History of coronary heart disease (i.e chronic stable angina, myocardial infarction or acute coronary syndrome). 5. History of a stroke or other cerebrovascular accident (i.e. transient ischaemic attack or reversible ischaemic neurological deficit). 6. Severe hepatic impairment 7. Treatment with agents causing torsades de pointes 8. Lactation 9. Contraindications to any of the investigational medicinal products as per the SmPc of drugs studied 10. Known or suspected secondary hypertension. 11. Any other concomitant illness, physical or mental impairment that could interfere with the effective conduct of the study. 12. Pregnancy or those of child-bearing age who are not taking reliable contraception. 13. History of Gout. 14. Serum potassium less than 3.5mmol/L at screening.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Change in biochemical markers of oxidative stress and MMP-2 & 9Timepoint: Changes from baseline to 2,4 and 6 months;Changes in central arterial blood pressure (carotid artery)Timepoint: Changes in central arterial blood pressure from baseline to 2,4 and 6 months;Changes in local carotid arterial stiffnessTimepoint: Changes in local carotid stiffness from baseline to 2,4 and 6 months | — |
Primary
| Measure | Time frame |
|---|---|
| Changes in aortic stiffness by measuring carotid to femoral pulse wave velocity (cf-PWV)Timepoint: At baseline, 2 month, 4 month and 6 month | — |
Countries
India
Contacts
Public ContactSatish G Patil
SDM College of Medical Sciences and Hospital
Outcome results
None listed